Sunrest LifescienceShare price, financial results, shareholding and management
- Market cap
- ₹15 cr
- Stock P/E
- 1.9peers 17.1
- Book value
- ₹47.6
- Price to book
- 0.75
- EV / operating profit
- 2.9
- Market cap to sales
- 0.21
- ROCE · FY26
- 34.8%
- ROE · FY26
- 43.5%
- ROE, 3-year average
- 19.8%
- Operating margin · FY26
- 14.4%peers 17.7%
- Sales growth, 3 years
- 42.2%
- Profit growth, 3 years
- 57.7%
- Debt to equity
- 0.85peers 0.29
- Borrowings
- ₹17.5 cr
- Interest cover
- 8.1×
- Cash from business / op. profit
- -0%
- Debtor days
- 167
- Pledged
- 0.00%
- Promoter holding
- 53.50%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 484
- 52-week high / low
- ₹54 / ₹30
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Sunrest Lifescience share price chart
Close on 4 Nov 2026 · -4.83% on the day · Vol 1,600
Daily prices to 4 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 4 Nov 2026
- 1 month
- +0.0%
- 3 months
- -11.3%
- 6 months
- +0.0%
- 1 year
- -23.7%
- Traded a day, 20 days
- ₹0.02 cr
- Taken for delivery
- 91%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +112% | +296% |
| 3 years, a year | +42% | +58% |
Sunrest Lifescience revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months.
Sunrest Lifescience half-yearly results
SME companies report every six months · ₹ crore
| H1FY24 | H1FY25 | H2FY25 | |
|---|---|---|---|
| Sales | 12.48 | 15.39 | 17.73 |
| Expenses | 10.82 | 14.48 | 15.64 |
| Operating profit | 1.66 | 0.91 | 2.10 |
| OPM | 13.3% | 5.9% | 11.8% |
| Interest | 0.01 | 0.12 | 0.18 |
| Depreciation | 0.05 | 0.01 | 0.08 |
| Profit before tax | 1.60 | 0.78 | 1.83 |
| Net profit | 1.99 | 0.58 | 1.42 |
Sunrest Lifescience profit and loss
Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Sales | 10.64 | 15.79 | 24.60 | 24.64 | 29.48 | 33.41 | 70.83 |
| Expenses | 10.49 | 15.51 | 23.49 | 21.74 | 28.57 | 30.38 | 60.62 |
| Operating profit | 0.15 | 0.28 | 1.11 | 2.90 | 0.91 | 3.03 | 10.21 |
| OPM | 1.4% | 1.8% | 4.5% | 11.8% | 3.1% | 9.1% | 14.4% |
| Other income | 0 | 0 | 0.02 | 0.03 | 0 | 0 | 2.51 |
| Interest | 0 | 0.01 | 0.02 | 0.06 | 0.22 | 0.31 | 1.42 |
| Depreciation | 0.02 | 0.04 | 0.06 | 0.13 | 0.10 | 0.10 | 1.19 |
| Profit before tax | 0.13 | 0.23 | 1.05 | 2.74 | 0.59 | 2.62 | 10.11 |
| Tax rate | 76.9% | 21.7% | 25.7% | 25.5% | 61.0% | 22.9% | 20.9% |
| Net profit | 0.04 | 0.17 | 0.78 | 2.04 | 0.23 | 2.02 | 8 |
| EPS ₹ | 40 | 170 | 780 | 6.80 | 0.54 | 4.68 | 9.60 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
A tax rate above 60% or below zero (FY20, FY24) comes from tax charged on a small or negative profit, as reported.
Earnings per share before FY23 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Sunrest Lifescience profitability
Margins and returns on capitalLast year the company kept more from each rupee of sales than the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 1.4% | 1.8% | 4.5% | 11.8% | 3.1% | 9.1% | 14.4% |
| Tax rate | 76.9% | 21.7% | 25.7% | 25.5% | 61.0% | 22.9% | 20.9% |
| ROCE | · | 9.6% | 31.0% | 58.6% | 6.3% | 12.0% | 34.8% |
| ROE | · | 81.0% | 114.7% | 97.6% | 2.7% | 13.3% | 43.5% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Sunrest Lifescience debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take about as long to pay as they did in FY24.
Bars below the line are cash going out.
Sunrest Lifescience balance sheet
At each 31 March · ₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Equity capital | 0.01 | 0.01 | 0.01 | 3 | 4.29 | 4.29 | 4.29 |
| Reserves | 0.12 | 0.28 | 1.06 | 0.11 | 9.89 | 12.02 | 16.14 |
| Net worth | 0.13 | 0.29 | 1.07 | 3.11 | 14.18 | 16.31 | 20.43 |
| Borrowings | 2.27 | 2.31 | 3.24 | 2.14 | 6.16 | 12.05 | 17.46 |
| Other liabilities | 3.85 | 6.88 | 8.71 | 11.47 | 4.82 | 30.29 | 33.52 |
| Total liabilities | 6.25 | 9.48 | 13.02 | 16.72 | 25.16 | 58.65 | 71.41 |
| Fixed assets | 0.03 | 0.15 | 0.47 | 0.35 | 0.26 | 4.36 | 8.55 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0.02 | 0.02 | 0 | 0 |
| Other assets | 6.22 | 9.33 | 12.55 | 16.35 | 24.88 | 54.29 | 62.86 |
| Receivables | · | · | · | · | · | · | 32.46 |
| Inventory | · | · | · | · | · | · | 17.06 |
| Cash | · | · | · | · | · | · | 2.76 |
| Trade payables | · | · | · | · | · | · | 21.02 |
Sunrest Lifescience cash flow
₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | -0.90 | 0.15 | -0.44 | 1.15 | -14.80 | 2.92 | -0.05 |
| Cash from investing | -0.01 | -0.16 | -0.36 | -0.03 | -0.01 | -1.15 | -2.91 |
| Cash from financing | 1.11 | 0.04 | 0.90 | -1.15 | 14.64 | -0.33 | 3.99 |
| Net cash flow | 0.20 | 0.03 | 0.10 | -0.03 | -0.17 | 1.44 | 1.03 |
| Capital spending | · | · | · | · | · | · | 7.52 |
Working capital
Days
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 184 | 171 | 139 | 161 | 186 | 397 | 167 |
| Inventory days | 24 | 49 | 48 | 97 | 92 | 175 | 141 |
| Days payable | 175 | 206 | 166 | 212 | 69 | 417 | 173 |
| Cash conversion cycle | 33 | 14 | 21 | 46 | 209 | 156 | 135 |
| Working capital days | 70 | 47 | 47 | 63 | 211 | 228 | 156 |
Sunrest Lifescience peers and competitors
Listed SME companies in the same industryBy sales, Sunrest Lifescience is number 20 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Accretion Pharmaceuticals | 215 | 22.2 | 89.6 | 9.7 | 16.7% | 0.23 |
| Walpar Nutritions | 25 | 9.9 | 78.8 | 2.5 | 8.5% | 0.89 |
| Speciality Medicines | 142 | 10.9 | 75 | 13 | 18.0% | 0.10 |
| Shelter Pharma | 85 | 9.5 | 73 | 9 | 17.4% | 0.01 |
| Sunrest Lifescience | 15 | 1.9 | 70.8 | 8 | 14.4% | 0.85 |
| Onyx Biotec | 68 | - | 69.5 | -0.2 | 4.9% | 0.27 |
| Curis Lifesciences | 154 | 22.3 | 60.6 | 6.9 | 18.4% | 0.46 |
| Aptus Pharma | 779 | 168.7 | 46.6 | 4.6 | 16.0% | 0.31 |
| Bio Medica Laboratories | 205 | 17.4 | 43.1 | 11.8 | 45.6% | 1.51 |
| Himalaya Nutravedics India | 127 | 17.1 | 43.1 | 7.4 | 18.8% | 0.31 |
| Amwill Health Care | 89 | 8.0 | 43 | 11 | 30.0% | 0.00 |
| Median of the 10 others | 135 | 17.1 | 65.1 | 8.2 | 17.7% | 0.29 |
Sunrest Lifescience shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little less than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Sunrest Lifescience shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.91% | 69.91% | 69.91% | 69.91% | 53.50% | 53.50% | 53.50% | 53.50% |
| Foreign investors (FIIs) | 0.00% | 0.00% | 0.00% | - | - | - | - | - |
| Indian institutions (DIIs) | 0.00% | 0.00% | 0.00% | - | - | - | - | - |
| HNIs (over ₹2 lakh each) | 4.14% | 4.14% | 5.11% | 5.26% | 15.55% | 14.69% | 15.59% | 14.50% |
| Small holders (up to ₹2 lakh) | 20.73% | 20.69% | 19.84% | 19.02% | 20.47% | 20.21% | 20.77% | 21.51% |
| Companies and others | 5.22% | 5.26% | 5.14% | 5.81% | 10.48% | 11.60% | 10.14% | 10.49% |
| Number of shareholders | 505 | 487 | 459 | 455 | 498 | 491 | 492 | 484 |
The named holders are at 30 June 2026, beside 31 March 2026, each under the group the pattern files them in.
Sunrest Lifescience latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- Shareholding, 30 June 2026: promoters unchanged at 53.50%.
Sunrest Lifescience announcements
31 on record, latest first; each opens the filing on the exchange
- Structural Digital DatabaseSDD Compliance Certificate for the Quarter ended on 30th September, 2026PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Outcome of Board MeetingHeld on September 11, 2026 in relation to Dissolving the Right Issue due to non receipt of minimum subscription and other other mattersPDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on September 07, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 07, 2026PDF ↗
- Copy of Newspaper PublicationIn relation to Extention of Right Issue Closure Date from September 02, 2026 To September 11, 2026PDF ↗
- Rights Issuethat Board of Directors at its meeting held on September 02, 2026, has decided to extend the issue of equity shares on rights basis in the ratio of 1 : 1, i.e 1PDF ↗
- Updates'General Operational Update'PDF ↗
- Copy of Newspaper PublicationCopy of Post Newspaper Publication for the Annual General Meeting to be held on 07th September, 2026PDF ↗
- Shareholders meetingNotice of Annual General Meeting to be held on September 07, 2026PDF ↗
- Shareholders meetingNotice of Annual General Meeting to be held on September 07, 2026PDF ↗
Sunrest Lifescience annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Sunrest Lifescience share split, bonus and dividends
From the corporate actions the company announces on the exchange
- Rights issueRIGHTS 1:1 @ PREMIUM RS 25/-ex-date 10 Aug 2026
- Rights issueRIGHTS 1:1 @ PREMIUM RS 25/-ex-date 23 March 2026
Checks we ran on Sunrest Lifescience's data · 11
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- !For FY26 the exchange filing's profit lines do not add up as read, so the figures shown are from the results page instead.
- iThe halves of FY26 are shown standalone and the full year consolidated, as the company files them, so the two need not add up.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (42,91,200 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- !The two half-years of FY26 add up to ₹33.3 cr of sales against ₹70.8 cr for the full year, so the half-years of FY26 are held back.
- !Earnings per share changes basis between FY22 (₹780.00) and FY23 (₹6.80) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY20 to FY26.
- iPrices run to the close on 12 Oct 2026, from the exchange's daily figures.
Questions people ask about Sunrest Lifescience
What does Sunrest Lifescience do?
Sunrest Lifescience is an SME company listed on NSE Emerge, in pharmaceuticals & biotechnology.
What is the share price of Sunrest Lifescience?
₹35.5 at the close on 4 Nov 2026, from the exchange's daily figures.
What is the market cap of Sunrest Lifescience?
₹15 cr at the close on 4 Nov 2026, on 42,91,200 shares.
What is the P/E of Sunrest Lifescience?
1.9 times FY26 profit at the close on 4 Nov 2026 (our arithmetic).
What are Sunrest Lifescience's revenue and profit?
Revenue ₹71 cr and profit after tax ₹8 cr in FY26.
Who are the promoters of Sunrest Lifescience?
The promoter group; promoters held 53.50% at 30 June 2026.
What is Sunrest Lifescience's website?
www.sunrestlifescience.com
More SME companies like Sunrest Lifescience
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Mono PharmacareMONOPHARMA · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹18 cr
- Dipna PharmachemDPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹11 cr
- Walpar NutritionsWALPAR · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2021Market cap ₹24 cr
- Goldline PharmaceuticalGLPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹30 cr
- Ganga PharmaceuticalsGANGAPHARM · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹7 cr
- Medicamen OrganicsMEDIORG · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹39 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2023 →
Built from 31 exchange announcements, 8 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.